Sustained virologic control in SIV <sup>+</sup> macaques after antiretroviral and α <sub>4</sub> β <sub>7</sub> antibody therapy
Siddappa N. Byrareddy(Emory University), James Arthos(National Institute of Allergy and Infectious Diseases), Claudia Cicala(National Institute of Allergy and Infectious Diseases), François Villinger(Emory University), Kristina Ortiz(Emory University), Dawn Little(Emory University), Neil Sidell(Emory University), Maureen A. Kane(University of Maryland, Baltimore), Jianshi Yu(University of Maryland, Baltimore), Jace W. Jones(University of Maryland, Baltimore), Philip J. Santangelo(The Wallace H. Coulter Department of Biomedical Engineering), Chiara Zurla(The Wallace H. Coulter Department of Biomedical Engineering), Lyle R. McKinnon(Centre for the AIDS Programme of Research in South Africa), Kelly B. Arnold(University of Michigan), Caroline E. Woody(University of Michigan), Lutz Walter(German Primate Center), Christian Roos(German Primate Center), Angela Noll(German Primate Center), Donald Van Ryk(National Institute of Allergy and Infectious Diseases), Katija Jelicic(National Institute of Allergy and Infectious Diseases), Raffaello Cimbro(Johns Hopkins University), Sanjeev Gumber(Emory University), Michelle D. Reid(Emory University), Volkan Adsay(Emory University), Praveen K. Amancha(Emory University), Ann E. Mayne(Emory University), Tristram G. Parslow(Emory University), Anthony S. Fauci(National Institute of Allergy and Infectious Diseases), Aftab A. Ansari(Emory University)
Cited by 202
Abstract
Antibodies sustain viral control For many infected individuals, antiretroviral therapy (ART) means that an HIV-1 diagnosis is no longer a death sentence. But the virus persists in treated individuals, and complying with the intense drug regimen to keep virus loads down can be challenging for patients. Seeking an alternative, Byrareddy et al. treated ART-suppressed monkeys with antibodies targeting α4β7 integrin. When ART was halted in the antibody-treated animals, viral loads stayed undetectable, and normal CD4 T cell counts were maintained for over 9 months—and persisted—even after stopping the antibody therapy. Science , this issue p. 197
Related Papers
No related papers found
Powered by citation graph analysis